These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 8274287

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Pharmacokinetics and biotransformation following topical use of the local corticoid prednicarbate].
    Kellner HM, Eckert HG, Fehlhaber HW, Hornke I, Oekonomopulos R.
    Z Hautkr; 1986; 61 Suppl 1():18-40. PubMed ID: 3705671
    [Abstract] [Full Text] [Related]

  • 3. Prednicarbate after different forms of administration. Plasma levels of drug and metabolites and effects on endogenous cortisol levels in humans.
    Barth J, Hochhaus G, Derendorf H, Lehr KH, Höhler T, Moellmann H.
    Curr Probl Dermatol; 1993; 21():147-56. PubMed ID: 8299368
    [No Abstract] [Full Text] [Related]

  • 4. Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts.
    Gysler A, Lange K, Korting HC, Schäfer-Korting M.
    Pharm Res; 1997 Jun; 14(6):793-7. PubMed ID: 9210199
    [Abstract] [Full Text] [Related]

  • 5. Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin.
    Gysler A, Kleuser B, Sippl W, Lange K, Korting HC, Höltje HD, Korting HC.
    Pharm Res; 1999 Sep; 16(9):1386-91. PubMed ID: 10496654
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids.
    Lange K, Kleuser B, Gysler A, Bader M, Maia C, Scheidereit C, Korting HC, Schäfer-Korting M.
    Skin Pharmacol Appl Skin Physiol; 2000 Sep; 13(2):93-103. PubMed ID: 10754457
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vitro skin absorption and drug release - a comparison of six commercial prednicarbate preparations for topical use.
    Lombardi Borgia S, Schlupp P, Mehnert W, Schäfer-Korting M.
    Eur J Pharm Biopharm; 2008 Feb; 68(2):380-9. PubMed ID: 17574402
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic/pharmacodynamic modelling of effects of dexamethasone and prednisolone in combination with endogenous cortisol on lymphocyte counts and systemic markers of bone turn over and inflammation in healthy and asthmatic men.
    Dubois EF, Derks MG, Schweitzer DH, Zwinderman AH, Dekhuijzen PN, van Boxtel CJ.
    Eur J Clin Pharmacol; 2004 Jul; 60(5):315-28. PubMed ID: 15150679
    [Abstract] [Full Text] [Related]

  • 12. Effects of oral and inhaled corticosteroid on lymphocyte beta2-adrenoceptor function in asthmatic patients.
    Tan KS, McFarlane LC, Lipworth BJ.
    Br J Clin Pharmacol; 1997 Dec; 44(6):565-8. PubMed ID: 9431832
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Reaction of autogenous cortisol production in patients with extensive psoriasis vulgaris or atopic dermatitis following external administration of a 0.25% prednicarbate salve (W/O emulsion)].
    Ernst TM.
    Z Hautkr; 1986 Dec; 61 Suppl 1():74-9. PubMed ID: 3010589
    [Abstract] [Full Text] [Related]

  • 15. Transcriptional activity of potent glucocorticoids: relevance of glucocorticoid receptor isoforms and drug metabolites.
    Spika I, Hammer S, Kleuser B, Korting HC, Schäfer-Korting M.
    Skin Pharmacol Appl Skin Physiol; 2003 Dec; 16(3):143-50. PubMed ID: 12677094
    [Abstract] [Full Text] [Related]

  • 16. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids.
    Schäfer-Korting M, Korting HC, Kerscher MJ, Lenhard S.
    Clin Pharmacol Ther; 1993 Oct; 54(4):448-56. PubMed ID: 8222488
    [Abstract] [Full Text] [Related]

  • 17. [Synthesis of prednicarbate, an non-halogenated topical anti-inflammatory derivative of prednisolone-17-ethylcarbonate esters].
    Stache U, Fritsch W, Rupp H, Hitzel V, Fehlhaber HW.
    Arzneimittelforschung; 1985 Oct; 35(12):1753-7. PubMed ID: 4096725
    [Abstract] [Full Text] [Related]

  • 18. The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration.
    Täuber U, Haack D, Nieuweboer B, Kloss G, Vecsei P, Wendt H.
    Int J Clin Pharmacol Ther Toxicol; 1984 Jan; 22(1):48-55. PubMed ID: 6698661
    [Abstract] [Full Text] [Related]

  • 19. [Prednicarbate--the epidermis-corticoid among the topical corticoids].
    Hautarzt; 1998 Apr; 49(4 Suppl):1-16. PubMed ID: 9595306
    [No Abstract] [Full Text] [Related]

  • 20. L-Carnitine ester of prednisolone: pharmacokinetic and pharmacodynamic evaluation of a type I prodrug.
    Mo J, Lim LY, Zhang ZR.
    Int J Pharm; 2014 Nov 20; 475(1-2):123-9. PubMed ID: 25173636
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.